+91 9811647894
clininfo@clinicounselors.com

Diabetes News

‘New Era’ of Type 2 Diabetes Treatment as LEADER Unveiled?
NEW ORLEANS, June 13 2016 Miriam E Tucker. http://www.medscape.com/viewarticle/864729

Details of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial of the glucose-lowering drug liraglutide (Victoza, Novo Nordisk), showing that it significantly reduced the rates of major adverse cardiovascular events in type 2 diabetes patients at elevated cardiovascular risk, were reported today.

The study is the second such mandated FDA cardiovascular safety study for a diabetes drug to show cardiovascular benefit, rather than just lack of harm, on top of standard therapy in type 2 diabetes patients at high cardiovascular risk after the EMPA-REG trial, and the first with an agent from the glucagonlike peptide 1 (GLP-1) receptor agonist class. Results of a previous trial with another GLP-1 agonist, ELIXA, were neutral.

Why Diabetes and Heart Disease is a Deadly Combination
IANS, Modified: June 13, 2016 16:37 IST

People with Type 2 diabetes who are admitted into the hospital for congestive heart failure face a one in four chance of dying over the next 18 months, a global study has warned.

The findings paint a much grimmer picture of the outcome for diabetes patients with severe heart disease. “Type 2 diabetes accompanied by an acute coronary syndrome needs much more attention, especially in order to prevent yet another major cardiac event,” said main investigator William.B.White from University of Connecticut Health Centre (UConn Health).

Patients with Type 2 diabetes have two to three times the heart disease risk of the general population. This is partly because obesity and other illnesses such as hypertension and elevated cholesterol contribute to both diseases, but there are concerns that some of the medications that help control blood sugar may also damage the heart.

Even insulin, a hormone that healthy people make naturally but some patients with Type 2 diabetes often need as a medication, can contribute to heart disease. In new research, the researchers provide new insights on mortality in the earlier EXAMINE trial from a series of new analyses.

In the earlier EXAMINE study, the researchers recruited 5,380 patients with Type 2 diabetes after the patient had a major but non-fatal acute coronary syndrome such as a heart attack, or hospitalisation for unstable angina.

The researchers randomly assigned the patients to take either anti-diabetic drug alogliptin or a placebo and then followed their progress for up to three years. “People with Type 2 diabetes admitted to the hospital for heart failure faced a 24 to 28 percent chance of death on anti-diabetic drug aloglipin or placebo, respectively,” the authors noted in the new study.

That’s more than five times the risk of death seen in the patients who had no additional non-fatal cardiovascular event. “It’s a very dramatic result. A person with Type 2 diabetes requiring hospitalisation for heart failure in the EXAMINE trial was a harbinger of a very poor outcome,” added White. The results were presented at the American Diabetes Association’s (ADA) annual meeting in New Orleans and published in the ADA journal Diabetes Care.

Combination of Stem Cell and Drug Therapy Could Reverse Type 2 Diabetes
R. Sam Barclay | Published on May 19, 2015 www.healthline.com

Stem cell research is heralding a new age of possible medical treatments as scientists use them to grow transplantable cells and organs. Now, it appears those new treatments might include one for type 2 diabetes. Existing research has already found avenues to treat type 1diabetes. This less-common, early-onset form of diabetes occurs when the body’s immune system attacks and destroys insulin-producing cells in the pancreas, often while fighting an infection elsewhere in the body. By using stem cells, doctors can grow new insulin-producing cells to replace those that the pancreas has lost. However, type 2 diabetes – which makes up 90% of diabetes cases worldwide – is harder to treat. It typically occurs in adults as a result of excess weight or hormonal imbalances.

While people with type 2 diabetes do lose some of their insulin-producing cells, their primary problem is elsewhere. Their cells have become resistant to insulin. Although insulin is present in the body, the cells can no longer use insulin to keep blood sugar levels in check. Simply regrowing the missing insulin-producing cells is not enough to solve the problem.

Drug shows promise for treating prediabetes and type 2 diabetes
Diabetes.co.uk Wed, 25 June 2014

Results from a pilot study by researchers in America shows that the medication, codenamed NM504, improves the body’s response to carbohydrate intake by altering bacteria in the gastrointestinal (GI) tract and other microorganisms (microbiota) and their environment in specific ways. Scientists believe the GI microbiome may play a vital role in controlling the body’s metabolism, and a recent study found evidence that microbial imbalance (dysbiosis) in the gut plays a role in the development of type2 diabetes.

Combination therapy could kickstart insulin production in type 1 diabetics
Diabetes.co.uk Wed, 25 Jun 2014

The treatment – a combination of two different medications – has been developed and tested by scientists in the U.S. who describe the results of their first trial as “profound”. To begin with, problematic immune system cells that may be behind a patient’s inability to produce insulin are flushed out and destroyed using a medication called Thymoglobulin, which was initially developed for use in organ transplants. Next, a cancer-treating medication called Neulasta is used to stimulate the production of new and potentially beneficial immune cells. The patients received the combination therapy for two weeks and were then followed for a year. Another eight patients were given a placebo. By the end of the year, insulin production had improved in those treated with the cocktail, indicating the preservation and increase of insulin-making beta cells.

Researchers claim they may be able to cure diabetes… and the key is already in your body
POSTED 9:08 AM, July 10, 2014,BY Posts by KFOR-TV & K. Querry” KFOR-TV & K. QUERRY AND Posts by NBC News NBC NEWS

GOLDEN VALLEY, Minn. – Cells found in the body may be the key to curing diabetes in the future, according to new research. Since he was 10-years-old, Drew Reiter has been testing his blood sugar and giving himself four to five insulin shots a day. Reiter has Type 1 diabetes, meaning his body does not make insulin to regulate his blood sugar.”I feel like I’m pretty on top of things but it’s still hard to regulate,” he said. Now, there’s hope of a possible cure. A new study out of Columbia University Medical Center has found that cells in the small intestine can produce insulin and regulate blood sugar effectively when researchers turn off the FOX01 gene in those cells.
The next step will then be human clinical trials. More time will be needed to test safety. If it’s successful, the treatment could be available to people with Type 1 or Type 2 diabetes.

Diabetes could be cured as scientists find cause of disease….
The Telegraph, By Sarah Knapton” Sarah Knapton, Science Correspondent,7:00AM BST 21 Aug 2014

Scientists at Manchester University have discovered that the hormone amylin can clump together and stop cells producing insulin
Diabetes could be cured after scientists discovered that toxic clumps of a hormone stop cells producing insulin. Scientists at Manchester University have found that both Type 1 and Type 2 diabetes are driven by the same underlying mechanism. The findings suggest that both forms occur when the hormone amylin begins to clump together, surrounding cells, and preventing them from producing insulin.
Insulin is essential for moving sugar from the blood stream into muscles and fatty tissue to provide energy. But too little insulin allows dangerous levels of glucose to build up in the blood, causing damage to the heart kidneys, eyes and nerves.
However the new finding could pave the way for drugs which stop the amylin build-up in the first place or dissolve clumps which are already present.
Previous research suggested that this was the cause of Type 2 diabetes. But now scientists believe it could also explain Type 1, which occurs in childhood.
The team hopes to have potential medicines ready to go into clinical trials in the next two years and it is anticipated that these will be tested in both type-1 and type-2 diabetic patients.
Clinical trials are being planned with research groups in England and Scotland.
However diabetes charities said people should adopt healthier lifestyles to avoid Type 2 diabetes rather than wait for a pill.
Dr Alasdair Rankin, Director of Research at Diabetes UK, said: “Amylin has been studied in diabetes for many years. Type 1 and Type 2 diabetes are two very different conditions. We don’t know exactly what causes Type 1 but many possibilities have been suggested and amylin is just one of these.”